Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic
syndrome.
PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating
anemia in patients who have myelodysplastic syndrome.